Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment

[Business Wire] – Gilead Sciences, Inc. today announced that the company’s Marketing Authorization Application for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide has been fully validated and is . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment Similar Articles: Market Update (NASDAQ:GILD): Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19 Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead agrees 41,000 eur hep-C drug price for 12 week treatment Company Update (NASDAQ:GILD): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount